Signant Health Report issue

For profit Phase 3
Founded: Lansdale PA United States (2000)

Organization Overview

First Clinical Trial
2017
NCT03085797
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Signant Health

Active Ingredients

Drugs in Phase 3 Trials (2)

mepolizumab (Nucala) (2 trials)

mometasone (elocon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Nasal Polyps (Phase 3)

Polyps (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2